GFP Stable Cell Line - Colon26

Interferons (IFN)‐α, ‐β, and ‐γ directly combat cancer by inhibiting cancer cell growth or inducing cell death. The researchers developed a method to generate myeloid cells with proliferative capabilities from pluripotent stem cells, termed iPS-ML, which resemble physiological macrophages and can infiltrate cancer tissues. They observed the therapeutic effects of human iPS-ML cells expressing interferon β (iPS-ML/IFN-β) in xenograft cancer models. To assess the effects in a system mimicking host immune responses, they created a mouse equivalent, ES-ML/IFN, derived from embryonic stem cells and producing IFN-β (β-ML) or IFN-γ (γ-ML). By disrupting MHC genes using CRISPR/Cas9, they tested these cells in allogeneic BALB/c mice with colon cancer. Treatment with β-ML, but not γ-ML, inhibited cancer growth and enhanced T cell infiltration into cancer tissues. The therapy increased immune cell numbers in lymphoid organs and sensitized cancer antigen-specific CD8+ T cells and NK cells, with CD8+ T cells being crucial for the therapeutic effect.

Figure 1. The researchers examined the infiltration of β‐ML and γ‐ML into cancer tissues by injecting Colon26/GFP cells into mice, followed by injection of PKH26-labeled β‐ML and γ‐ML. They observed co-localization of ES‐ML/IFN with cancer cells, indicating accumulation at the cancer lesion site. (Umemoto S, et al., 2019).